Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,

NCT07614438 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: 2025-525153-39-00
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. Perioperative hemodynamic management often requires the administration of a vasopressor to maintain the arterial pressure above a specific threshold of 65 mmHg. Low dose of vasopressin increases systemic arterial pressure with minimal effects on the pulmonary circulation. This profile suggests that vasopressin may be an ideal agent for vasopressor support in the high-risk population of patients with pulmonary hypertension. To date, there is no data on the use of vasopressin in patient undergoing PEA surgery. The interesting properties of vasopressin - specifically, its ability to increase systemic arterial resistance while having a low impact on pulmonary resistance and offering potential renal protective effects - are highly advantageous in the specific subset of patient scheduled for PEA. The investigators aim to conduct a randomized single center open label study to compare the effect of vasopressin compared to norepinephrine on mean pulmonary artery pressure after PEA surgery. The primary objective of this study is to determine whether the use of vasopressin compared to norepinephrine decrease the mean pulmonary artery pressure after PEA surgery. Participation to the study involves follow up at day 30 following surgery.

Conditions

Anesthesia; Pulmonary Hypertension; Chronic Pulmonary Thromboembolism; Vasopressor

Outcome Measures

Primary Outcomes (1)

• mPAP in millimeter of mercury (mmHg) measured by the Swan-Ganz catheter in the operating room.

  at the end of skin closure immediately following the completion of the PEA procedure.

Study Arms (2)

Vasopressin

EXPERIMENTAL

Drug: Vasopressin

Norepinephrine

ACTIVE COMPARATOR

Drug: Norepinephrine

Interventions

Vasopressin DRUG

After inclusion and randomization, the intervention group will receive Vasopressin at a concentration of 0.04 IU/mL by continuous infusion (from 10 ml/h to 50 ml/h, by step of 3 ml/h) to target a MAP \> 65 mmHg according to the protocol Vasopressin is continued for the first 24 hours in the intensive care unit following the same protocol.

Vasopressin

Norepinephrine DRUG

After inclusion and randomization, the control group will receive norepinephrine at a concentration of 16 μg/mL by continuous infusion (from 10 ml/h to 50 ml/h, by step of 3 ml/h) to target a MAP \> 65 mmHg according to the protocol. Norepinephrine is continued for the first 24 hours in the intensive care unit following the same protocol.

Norepinephrine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years;
• Patient scheduled for pulmonary endarterectomy surgery;
• In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;
• Affiliation to the French social care service;
• Patient able to understand and sign a written informed consent form.

You may not qualify if:

• Emergency surgery;
• Mesenteric ischemia and/or acute coronary syndrome within the month preceding the intervention;
• Patients with documented mesenteric artery stenosis;
• Impossibility to insert the pulmonary artery catheter (anatomical or technical issue);
• Preoperative administration of norepinephrine and/or inotropic drugs (dobutamine, isoproterenol, epinephrine) or patients assisted by veno-venous or veno-arterial ECMO before surgery;
• Known allergy to the active substance vasopressin or to any of its excipients;
• Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);
• mPAP\<25 mmHg on preoperative right heart catheterization;
• Patient with preoperative natremia below 130 mol/L;
• Patient participating to another interventional clinical trial;
• For females only: documented pregnancy or lactation;
• Patient under tutorship, curatorship or legal protection;
• Patient deprived of liberty.

Sponsors & Collaborators

• Fondation Hôpital Saint-Joseph: lead

Study Sites (1)

Hôpital Marie Lannelongue

Le Plessis-Robinson, 92350, France

Location

MeSH Terms

Conditions

Hypertension, Pulmonary

Interventions

Vasopressins; Norepinephrine

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins; Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Biogenic Monoamines; Biogenic Amines; Catecholamines; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2026
• First Posted: May 29, 2026
• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): August 2, 2026
• Study Completion (Estimated): September 1, 2028
• Last Updated: June 2, 2026

Record last verified: 2026-03

Locations

FR (1)